| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We investigated whether tumor-specific mutations could be detected in circulating tumor DNA (ctDNA) from the peripheral blood in patients with gastric cancer or imatinib-resistant GIST.
Cell-free DNA was extracted in blood samples in 6 patients with gastric cancer. Identical TP 53 mutations could be detected in ctDNA in 3 of the 6 patients. All 3 patients had extremely progressive disease, and the fraction rates of ctDNA were also consistent with tumor volume and disease course. Regarding GIST, imatinib-resistant lesions had single nucleotide substitutions in C-KIT exon 13 in three patients and exon 18 in one patient. Identical secondary C-KIT mutations could be detected in ctDNA with a mutant fraction range of 0.010- 9.385%, and the fraction rate of ctDNA was consistent with tumor volume and disease course.
|
